Transcend Therapeutics
This study is evaluating the long-term safety and efficacy of TSND-201 in adults with PTSD. Participants that have completed a double-blind clinical trial with TNSD-201 for PTSD will be invited to participate in this open-label extension trial. Each participant will be able to receive up to three Treatment Courses over the duration of the study (up to 48 weeks). Each Treatment Course includes 4 dosing sessions, spaced one week apart.
Inclusion Criteria: * Completion of a double-blind Transcend-sponsored clinical trial with TSND-201 (e.g., TSND201-PTSD-301) and considered in good standing with the study site. * Proficient in communication (verbal and reading) to complete interviews and written questionnaires. * Agree to not participate in any other interventional clinical trials for the duration of this study. Exclusion Criteria: * Experienced an intolerable side effect following dosing with TSND-201 in the prior study. * Had significant deviation(s)/non-compliance in parent study in the opinion of the Investigator which…
TSND-201 capsules, given orally; where a course of treatment includes dosing with TSND-201 once a week for four consecutive weeks